peplexicon
Choose your depth

Context, anatomy, and key evidence

← Peptide library

neuropeptide

VIP

Published evidence · coverage incomplete
Anatomical contextAnatomy connections are not mapped yet.

No body region is highlighted until this profile has a supported anatomical connection. This does not mean the peptide has no biological effects.

Read published mechanism findings ↓

At a glance

What is it—and why does it matter?

The label warns that bone marrow suppression can be severe or life-threatening and includes multiple cytopenias. The dosage form/strength specifies concentration at calibration time and total activity per single-dose vial at administration time. The labeled use includes treating PSMA-positive metastatic androgen pathway modulation-naïve or -sensitive prostate cancer in adults, with PLUVICTO given together with an ARPI.

Sources for this introduction: [1] [2] [3]

This published profile is a reference in progress. Findings retain their source context; missing topics are marked below.

What is it?

A molecule, not a product name.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

How does it work?

Target, response, and disposition.

Pharmacokinetics

Systemic exposure (AUC) and peak blood concentration (Cmax) are reported as geometric mean values (with geometric mean coefficient of variation) at the recommended dosing regimen.

Sources[1]dailymedThese highlights do not include all the information needed to use PLUVICTO safely and effectively. See full prescribing information for PLUVICTO.PLUVICTO®(lutetium Lu 177 vipivotide tetraxetan) injection, for intravenous useInitial U.S. Approval: 2022The blood lutetium Lu 177 vipivotide tetraxetan area under the curve (AUC) is 52.3 ng.h/mL (31.4%) and the maximum blood concentration (Cmax) is 6.58 ng/mL (43.5%) at the recommended dosage.
Reported result
AUC 52.3 ng.h/mL (31.4%); Cmax 6.58 ng/mL (43.5%)
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “The blood lutetium Lu 177 vipivotide tetraxetan area under the curve (AUC) is 52.3 ng.h/mL (31.4%) and the maximum blood concentration (Cmax) is 6.58 ng/mL (43.5%) at the recommended dosage.”

    These highlights do not include all the information needed to use PLUVICTO safely and effectively. See full prescribing information for PLUVICTO.PLUVICTO®(lutetium Lu 177 vipivotide tetraxetan) injection, for intravenous useInitial U.S. Approval: 2022 · 12.3 Pharmacokinetics

    dailymed:14908037-2892-4d98-a053-253ce35afb1a:9f7e3d7af549:9f7e3d7af549

What has been studied?

What the evidence says.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Risks and interactions

Risks, organized for scanning.

Safety findings

The label includes a warning that kidney toxicity may be severe.

Sources[1]dailymedThese highlights do not include all the information needed to use PLUVICTO safely and effectively. See full prescribing information for PLUVICTO.PLUVICTO®(lutetium Lu 177 vipivotide tetraxetan) injection, for intravenous useInitial U.S. Approval: 2022PLUVICTO can cause severe renal toxicity.
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “PLUVICTO can cause severe renal toxicity.”

    These highlights do not include all the information needed to use PLUVICTO safely and effectively. See full prescribing information for PLUVICTO.PLUVICTO®(lutetium Lu 177 vipivotide tetraxetan) injection, for intravenous useInitial U.S. Approval: 2022 · 5.3 Renal Toxicity

    dailymed:14908037-2892-4d98-a053-253ce35afb1a:9f7e3d7af549:9f7e3d7af549

Safety findings

The label warns that bone marrow suppression can be severe or life-threatening and includes multiple cytopenias.

Sources[1]dailymedThese highlights do not include all the information needed to use PLUVICTO safely and effectively. See full prescribing information for PLUVICTO.PLUVICTO®(lutetium Lu 177 vipivotide tetraxetan) injection, for intravenous useInitial U.S. Approval: 2022PLUVICTO can cause severe and life-threatening myelosuppression, including anemia, thrombocytopenia, leukopenia, and neutropenia.
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “PLUVICTO can cause severe and life-threatening myelosuppression, including anemia, thrombocytopenia, leukopenia, and neutropenia.”

    These highlights do not include all the information needed to use PLUVICTO safely and effectively. See full prescribing information for PLUVICTO.PLUVICTO®(lutetium Lu 177 vipivotide tetraxetan) injection, for intravenous useInitial U.S. Approval: 2022 · 5.2 Myelosuppression

    dailymed:14908037-2892-4d98-a053-253ce35afb1a:9f7e3d7af549:9f7e3d7af549

Products and regulatory status

Same ingredient. Different records.

Regulatory status

The labeled use includes treating PSMA-positive metastatic androgen pathway modulation-naïve or -sensitive prostate cancer in adults, with PLUVICTO given together with an ARPI.

Sources[1]dailymedThese highlights do not include all the information needed to use PLUVICTO safely and effectively. See full prescribing information for PLUVICTO.PLUVICTO®(lutetium Lu 177 vipivotide tetraxetan) injection, for intravenous useInitial U.S. Approval: 2022PLUVICTO is indicated in combination with androgen receptor pathway inhibitor (ARPI) therapy for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic androgen pathway modulation-naïve or -sensitive (mAPMN/S) prostate cancer.
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “PLUVICTO is indicated in combination with androgen receptor pathway inhibitor (ARPI) therapy for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic androgen pathway modulation-naïve or -sensitive (mAPMN/S) prostate cancer.”

    These highlights do not include all the information needed to use PLUVICTO safely and effectively. See full prescribing information for PLUVICTO.PLUVICTO®(lutetium Lu 177 vipivotide tetraxetan) injection, for intravenous useInitial U.S. Approval: 2022 · 1.1 Metastatic Androgen Pathway Modulation-Naïve or -Sensitive Prostate Cancer

    dailymed:14908037-2892-4d98-a053-253ce35afb1a:9f7e3d7af549:9f7e3d7af549

Administration context

The practical clinical context.

Dose records

The recommended regimen for lutetium Lu 177 vipivotide tetraxetan in mAPMN/S prostate cancer is a fixed activity dose administered on a 6-week cycle for up to 6 doses, alongside ARPI therapy, with stopping criteria for progression or toxicity.

Sources[1]dailymedThese highlights do not include all the information needed to use PLUVICTO safely and effectively. See full prescribing information for PLUVICTO.PLUVICTO®(lutetium Lu 177 vipivotide tetraxetan) injection, for intravenous useInitial U.S. Approval: 2022The recommended dosage of PLUVICTO in combination with ARPI is 7.4 GBq (200 mCi) every 6 weeks for 6 doses, or until disease progression or unacceptable toxicity.
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “The recommended dosage of PLUVICTO in combination with ARPI is 7.4 GBq (200 mCi) every 6 weeks for 6 doses, or until disease progression or unacceptable toxicity.”

    These highlights do not include all the information needed to use PLUVICTO safely and effectively. See full prescribing information for PLUVICTO.PLUVICTO®(lutetium Lu 177 vipivotide tetraxetan) injection, for intravenous useInitial U.S. Approval: 2022 · 2.3 Recommended Dosage

    dailymed:14908037-2892-4d98-a053-253ce35afb1a:9f7e3d7af549:9f7e3d7af549

Dose records

The recommended regimen for lutetium Lu 177 vipivotide tetraxetan in androgen pathway modulation-resistant metastatic prostate cancer is 7.4 GBq (200 mCi) given every 6 weeks for up to 6 administrations, with discontinuation for progression or toxicity.

Sources[1]dailymedThese highlights do not include all the information needed to use PLUVICTO safely and effectively. See full prescribing information for PLUVICTO.PLUVICTO®(lutetium Lu 177 vipivotide tetraxetan) injection, for intravenous useInitial U.S. Approval: 2022The recommended dosage of PLUVICTO is 7.4 GBq (200 mCi) every 6 weeks for 6 doses, or until disease progression or unacceptable toxicity.
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “The recommended dosage of PLUVICTO is 7.4 GBq (200 mCi) every 6 weeks for 6 doses, or until disease progression or unacceptable toxicity.”

    These highlights do not include all the information needed to use PLUVICTO safely and effectively. See full prescribing information for PLUVICTO.PLUVICTO®(lutetium Lu 177 vipivotide tetraxetan) injection, for intravenous useInitial U.S. Approval: 2022 · 2.3 Recommended Dosage

    dailymed:14908037-2892-4d98-a053-253ce35afb1a:9f7e3d7af549:9f7e3d7af549

Dose records

The dosage form/strength specifies concentration at calibration time and total activity per single-dose vial at administration time.

Sources[1]dailymedThese highlights do not include all the information needed to use PLUVICTO safely and effectively. See full prescribing information for PLUVICTO.PLUVICTO®(lutetium Lu 177 vipivotide tetraxetan) injection, for intravenous useInitial U.S. Approval: 2022Injection: 1,000 MBq/mL (27 mCi/mL) of lutetium Lu 177 vipivotide tetraxetan at calibration time as a clear and colorless to slightly yellow solution in a single-dose vial containing 7.4 GBq (200 mCi) ± 10% at administration time.
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Injection: 1,000 MBq/mL (27 mCi/mL) of lutetium Lu 177 vipivotide tetraxetan at calibration time as a clear and colorless to slightly yellow solution in a single-dose vial containing 7.4 GBq (200 mCi) ± 10% at administration time.”

    These highlights do not include all the information needed to use PLUVICTO safely and effectively. See full prescribing information for PLUVICTO.PLUVICTO®(lutetium Lu 177 vipivotide tetraxetan) injection, for intravenous useInitial U.S. Approval: 2022 · 3 DOSAGE FORMS AND STRENGTHS

    dailymed:14908037-2892-4d98-a053-253ce35afb1a:9f7e3d7af549:9f7e3d7af549

Dose records

For certain adverse reactions, the label permits a single activity reduction to 5.9 GBq (160 mCi), explicitly prohibiting later re-escalation.

Sources[1]dailymedThese highlights do not include all the information needed to use PLUVICTO safely and effectively. See full prescribing information for PLUVICTO.PLUVICTO®(lutetium Lu 177 vipivotide tetraxetan) injection, for intravenous useInitial U.S. Approval: 2022The dose of PLUVICTO may be reduced by 20% to 5.9 GBq (160 mCi) once; do not re-escalate dose.
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “The dose of PLUVICTO may be reduced by 20% to 5.9 GBq (160 mCi) once; do not re-escalate dose.”

    These highlights do not include all the information needed to use PLUVICTO safely and effectively. See full prescribing information for PLUVICTO.PLUVICTO®(lutetium Lu 177 vipivotide tetraxetan) injection, for intravenous useInitial U.S. Approval: 2022 · 2.4 Dosage Modifications for Adverse Reactions

    dailymed:14908037-2892-4d98-a053-253ce35afb1a:9f7e3d7af549:9f7e3d7af549

Research status + gaps

What still needs better answers?

  • No publishable claim yet for: administration, contraindication, effect, identity, interaction, mechanism
  • 3 compiled claim(s) withheld by automated assurance: assurance_score_below_0.58 (2), assurance_score_below_0.72 (1), current_regulatory_source_required (1), extraction_ambiguity (3), high_risk_requires_regulatory_or_two_independent_sources (1), no_direct_support (3)

These are the limits of this profile, not an exhaustive list of scientific uncertainties.

References + discovery

Open the records yourself.

  1. These highlights do not include all the information needed to use PLUVICTO safely and effectively. See full prescribing information for PLUVICTO.PLUVICTO®(lutetium Lu 177 vipivotide tetraxetan) injection, for intravenous useInitial U.S. Approval: 2022 ↗

    dailymed · published 2026-08-12 · retrieved 2026-08-30T08:40:08Z

Publication history and provenance

Version 3 · Automated assessment · 2026-08-30T08:40:08Z

634810a5b9724891d622f198a9cfa64fffbb5d446dda78ef69fb856a16721725